other activities of Euro-CNS

Associate Society of the European Society of Pathology
In 2016, Euro-CNS joined the European Society of Pathology (ESP) as an Associate Society. The purpose of the partnership is to guarantee the continuity, stability, and visibility of neuropathology. A major task for Euro-CNS is to contribute for the ESP Congresses scientific and instructive program proposals focusing on neuropathology issues relevant for general pathology.

Neuropathology sessions at the European Congress of Pathology
The European Congress of Pathology will be held from 8-12 September 2018 in Bilbao, Spain. The aim of the organisers is to provide an up-to-date scientific programme covering all major areas of diagnostic, translational, molecular and investigative pathology. Special emphasis will be put on both recent discoveries in pathology, and the reinforcement of close clinico-pathological cooperation. The core programme will be prepared with a strong input from the ESP Working Groups. Euro-CNS, as an associate society, is involved with several sessions dealing with neuropathology:

Tuesday 11 September, 17:15-19:15 hrs
Symposium organized by Euro-CNS: Immuno-oncology in glioblastoma. New Models for the study for the quantitative analysis of the bra in tumor microenvironment – Juan García Vallejo (the Netherlands). 2. Immuno-Oncology in Glioblastomas: general considerations and practical aspects – Miguel Idoate (Spain). 3. Immuno Landscape in Gliomas: Mechanism of Treg infiltration and Sialic acid-Siglec interactions and possible prognostic and therapeutic implications – Gosse Adema (the Netherlands)

Tuesday 11 September, 14:45-16:45 hrs
Short Course organized by Euro-CNS: “Brain Tumours of children and young adults.
1. Diagnostic Challenges in Paediatric Brain Tumour Pathology after WHO 2016 – Teresa Ribalta (Spain)
2. Open questions. Are IDH wt lower grade gliomas all malignant? Are 1p19q non-deleted gliomas all astrocytic? – H.K. Ng (Hong Kong)
3. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas – Rachel Vaubel (USA)
4. The Molecular Landscape of Ependymomas: The New Diagnostic Paradigm – Eloy Rivas (Spain)
5. Determinants of sensitivity and resistance to immune checkpoint blockers in solid tumors: Opportunities and challenges for high grade gliomas – Dr. Kurt Schalper (USA).

In addition, there will be 2 jointly organized sessions:
Monday 10 September, 17:15-19:15 hrs
Oral Free Paper Session, jointly organized by the Ophthalmic Pathology Working Group and Euro-CNS.

Wednesday 12 September, 14:00-16:00 hrs
Joint Symposium by the Soft Tissue & Bone Pathology Working Group and Euro-CNS: “Crossing the border of soft tissue and neuropathology”. Program t.b.a.

For the detailed congress program please visit the ESP Congress website.

Assessment of the translational status of diagnostic molecular marker testing in adult diffuse glioma
Euro-CNS also engages in Patterns of diagnostic marker assessment in adult diffuse glioma: “Adelheid Wöhrer et al. present the results of a Euro-CNS survey on patterns of diagnostic marker assessment in diffuse glioma. This Euro-CNS survey is the first of its kind and shall set a baseline for future follow-up surveys. A total of 130 colleagues engaged in brain tumor diagnostics from 40 nations participated, including also representatives from a number of countries outside of Europe. The main aim of the survey was to assess the translational status of diagnostic molecular marker testing in diffuse gliomas after the release of the WHO 2016 brain tumor classification. The WHO 2016 classification has introduced for the first time an integrated diagnostic approach incorporating both tumor morphology and molecular information. The responses show that molecular marker testing is uniformly considered as highly relevant, and in most centers, molecular information is incorporated already in diagnostic assessments. However, there are substantial differences in access to molecular markers and techniques, and there is also a high level of heterogeneity of methods and platforms used for testing, even within the same countries. Further, the respondents express a high level of concern with regard to the validity of test assays and advocate the need for international harmonization of standards and consensus guidelines. The majority expressed willingness to actively engage in interlaboratory trials aiming at quality control. Euro-CNS could serve in future as a platform for the development of such international trials within Europe and beyond.” Quoted from the Editorial by Johannes Hainfellner in Clinical Neuropathology 2017-1.  For the published results of the survey click here.